Diversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms

Isoprenoid compounds are biologically ubiquitous, and their characteristic modularity has afforded products ranging from pharmaceuticals to biofuels. Isoprenoid production has been largely successful in Escherichia coli and Saccharomyces cerevisiae with metabolic engineering of the mevalonate (MVA)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David N. Carruthers, Taek Soon Lee
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	isoprenoids metabolic engineering synthetic biology non-model organisms C1 metabolism terpenes Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/246ecb2c251f4a3283ac4a25861fac05
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:246ecb2c251f4a3283ac4a25861fac05
record_format	dspace
spelling	oai:doaj.org-article:246ecb2c251f4a3283ac4a25861fac052021-12-02T11:21:49ZDiversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms1664-302X10.3389/fmicb.2021.791089https://doaj.org/article/246ecb2c251f4a3283ac4a25861fac052021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmicb.2021.791089/fullhttps://doaj.org/toc/1664-302XIsoprenoid compounds are biologically ubiquitous, and their characteristic modularity has afforded products ranging from pharmaceuticals to biofuels. Isoprenoid production has been largely successful in Escherichia coli and Saccharomyces cerevisiae with metabolic engineering of the mevalonate (MVA) and methylerythritol phosphate (MEP) pathways coupled with the expression of heterologous terpene synthases. Yet conventional microbial chassis pose several major obstacles to successful commercialization including the affordability of sugar substrates at scale, precursor flux limitations, and intermediate feedback-inhibition. Now, recent studies have challenged typical isoprenoid paradigms by expanding the boundaries of terpene biosynthesis and using non-model organisms including those capable of metabolizing atypical C1 substrates. Conversely, investigations of non-model organisms have historically informed optimization in conventional microbes by tuning heterologous gene expression. Here, we review advances in isoprenoid biosynthesis with specific focus on the synergy between model and non-model organisms that may elevate the commercial viability of isoprenoid platforms by addressing the dichotomy between high titer production and inexpensive substrates.David N. CarruthersDavid N. CarruthersTaek Soon LeeTaek Soon LeeFrontiers Media S.A.articleisoprenoidsmetabolic engineeringsynthetic biologynon-model organismsC1 metabolismterpenesMicrobiologyQR1-502ENFrontiers in Microbiology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	isoprenoids metabolic engineering synthetic biology non-model organisms C1 metabolism terpenes Microbiology QR1-502
spellingShingle	isoprenoids metabolic engineering synthetic biology non-model organisms C1 metabolism terpenes Microbiology QR1-502 David N. Carruthers David N. Carruthers Taek Soon Lee Taek Soon Lee Diversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms
description	Isoprenoid compounds are biologically ubiquitous, and their characteristic modularity has afforded products ranging from pharmaceuticals to biofuels. Isoprenoid production has been largely successful in Escherichia coli and Saccharomyces cerevisiae with metabolic engineering of the mevalonate (MVA) and methylerythritol phosphate (MEP) pathways coupled with the expression of heterologous terpene synthases. Yet conventional microbial chassis pose several major obstacles to successful commercialization including the affordability of sugar substrates at scale, precursor flux limitations, and intermediate feedback-inhibition. Now, recent studies have challenged typical isoprenoid paradigms by expanding the boundaries of terpene biosynthesis and using non-model organisms including those capable of metabolizing atypical C1 substrates. Conversely, investigations of non-model organisms have historically informed optimization in conventional microbes by tuning heterologous gene expression. Here, we review advances in isoprenoid biosynthesis with specific focus on the synergy between model and non-model organisms that may elevate the commercial viability of isoprenoid platforms by addressing the dichotomy between high titer production and inexpensive substrates.
format	article
author	David N. Carruthers David N. Carruthers Taek Soon Lee Taek Soon Lee
author_facet	David N. Carruthers David N. Carruthers Taek Soon Lee Taek Soon Lee
author_sort	David N. Carruthers
title	Diversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms
title_short	Diversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms
title_full	Diversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms
title_fullStr	Diversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms
title_full_unstemmed	Diversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms
title_sort	diversifying isoprenoid platforms via atypical carbon substrates and non-model microorganisms
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/246ecb2c251f4a3283ac4a25861fac05
work_keys_str_mv	AT davidncarruthers diversifyingisoprenoidplatformsviaatypicalcarbonsubstratesandnonmodelmicroorganisms AT davidncarruthers diversifyingisoprenoidplatformsviaatypicalcarbonsubstratesandnonmodelmicroorganisms AT taeksoonlee diversifyingisoprenoidplatformsviaatypicalcarbonsubstratesandnonmodelmicroorganisms AT taeksoonlee diversifyingisoprenoidplatformsviaatypicalcarbonsubstratesandnonmodelmicroorganisms
_version_	1718395928367333376

Diversifying Isoprenoid Platforms via Atypical Carbon Substrates and Non-model Microorganisms

Ejemplares similares